Back to top
more

Apricus Biosciences, Inc (SEEL)

(Delayed Data from NSDQ)

$2.94 USD

2.94
367,490

+0.01 (0.34%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.92 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Brokerage Reports

0 items in cart

Seelos Therapeutics, Inc. [SEEL]

Reports for Purchase

Showing records 1 - 20 ( 65 total )

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 1

03/08/2022

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 2

11/26/2021

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 3

11/24/2021

Company Report

Pages: 5

Acquires Clinical-Stage Sublingual Ketamine from iX Biopharma; $20M Raise

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 4

11/09/2021

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 5

11/09/2021

Company Report

Pages: 6

3Q21: Pivotal SLS-005 SCA3 Trial to Start, Encouraging Early Clinical Data

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 12.50

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 6

10/27/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 7

10/26/2021

Company Report

Pages: 5

Presents More Details from Part 1 of Potentially Pivotal SLS-002 Trial

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 5.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 8

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SEEL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 9

09/27/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 10

09/27/2021

Company Report

Pages: 7

Getting Closer to SLS-002 Data and Increased Confidence; Rating to Buy/$8PT

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 11

08/10/2021

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 12

08/10/2021

Company Report

Pages: 5

2Q21: Still Not Sticking Our Necks Out for SLS-002

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 13

05/17/2021

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 14

05/17/2021

Company Report

Pages: 5

SLS-002 Delivers Seemingly Stellar Data, But We Need Controlled Results

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 15

05/12/2021

Daily Note

Pages: 21

Biotechnology- Pscychedelic Literature Review

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 16

03/12/2021

Industry Report

Pages: 79

Healthcare: Consumer Wellness -Psychedelics: An Emerging Market Opportunity

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 150.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 17

03/08/2021

Company Report

Pages: 5

Enrollment of First 16 MDD Patients Means Interim Look Likely Early 2Q21

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 18

03/08/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 19

03/01/2021

Industry Report

Pages: 3

Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Seelos Therapeutics, Inc.

Industry: Medical - Drugs

Record: 20

12/16/2020

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party